Douvlataniotis K, Titov A, Zeun J, Bilici M, Palashati H, Loh W, Rustad EH, Yang W, Tran TT, Lund-Johansen F, Bollineni RC, Kepple JD, Huth LP, Munthe LA, Boxaspen T, Schjesvold F, Waage A, Wagner DL, Bull KR, Hester J, Issa F, Giannakopoulou E, Olweus J(2026) TCR T cells targeting IgA- and IgG-expressing multiple myeloma Blood(in press) DOI 10.1182/blood.2025031897, PubMed 41770814
Tunheim G, Baranowska-Hustad M, Lund-Johansen F, Fossum E, Bhandari S, Kukule L, Møller TKR, Vikse EL, Bekkevold T, Oftung F, Robertson AH, Næss LM(2025) SARS-CoV-2 Infection With Alpha B.1.1.7 Virus Induced Higher Antibody Responses Than Earlier Non-VOC Variants During the First Waves of the COVID-19 Pandemic in Norway APMIS, 133(12), e70102 DOI 10.1111/apm.70102, PubMed 41376258
Aamodt AH, Ueland T, Boldingh M, Bezgal BE, Argren MB, Dunne CA, Otterdal K, Gregersen I, Bjerkeli V, Michelsen AE, Husøy A, Morsund ÅH, Devik K, Poole AC, Gjendemsjø KB, Schlüter K, Mathisen SM, Aalstad-Johansen M, Skattør TH, Sønnervik J, Boye TB, Popperud TH, Høgestøl EA, Harbo HF, Lund-Johansen Fet al.(2025) Altered amyloid plasma profile in patients with disabling headaches after SARS-CoV-2 infection and vaccination BMJ Neurol Open, 7(2), e001013 DOI 10.1136/bmjno-2024-001013, PubMed 40881041
Contact information: Group leader Fridtjof Lund-Johansen, Department of Immunology, Oslo University Hospital, Rikshospitalet, Tel: +47 23073016, E-mail: fridtjof.lund-johansen@rr-research.no
